Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain-containing protein 36C (ANKRD36C) is a member of the ankyrin repeat domain (ANKRD) protein family, characterized by multiple ankyrin repeat motifs that mediate protein–protein interactions[1][3]. The precise biological functions of ANKRD36C remain poorly understood, but it has been implicated in the pathogenesis of immune-mediated thrombotic thrombocytopenic purpura (iTTP), likely by affecting pathways related to protein glycosylation and inflammation[1]. The protein is predicted to have ion channel inhibitor activity and may participate in cell regulatory processes through its protein–protein interaction domains[3]. There is also evidence suggesting its involvement in cancer biology, such as oral squamous cell carcinoma[2]. Currently, ANKRD36C is not recognized as a direct therapeutic target, and no drugs are known to specifically act on it. Further research is required to elucidate its detailed roles in physiology and disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain-containing protein 36C (ANKRD36C).